과민성방광 치료에 있어서 항무스카린성 약제들에 대한 문헌검토: 2009

키워드

참고문헌 (80)

1. Abrams P, "The standardisation of terminology of lower urinary tract function: report from the Standar- disation Sub-committee of the International Continence Society", Neurourol Urodyn, 21, pp.167~178 (2002)
2. Ouslander JG, "Management of overactive bladder", N Engl J Med, 350, pp.786~799 (2004)
3. Liberman JN, "Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S", community-based survey, 57, pp.1044~1050 (2001)
4. 대한배뇨장애요실금학회, "과민성방광지침서", 메드랑, ~ (2007)
5. Andersson KE, "Pharmacologic Management of Storage and Emptying Failure. in: Campbell-Walsh Urology, ed. 9", pp.2079~2090 (2007), Saunders
6. Chess-Williams R, "Muscarinic receptors of the urinary bladder: Detrusor, urothelial and prejunctional", Auton Autacoid Pharmacol, 22, pp.133~145 (2002)
7. Gillespie JI, "Agonist and nerve induced phasic activity in the isolated whole bladder of the guinea pig: Evidence for two types of bladder activity", Exp Physiol, 88, pp.343~357 (2003)
8. Mansfield KJ, "Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing", Br J Pharmacol, 144, pp.1089~1099 (2005)
9. Hegde SS, "Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo", Br J Pharmacol, 120, pp.1409~1418 (1997)
10. Coyne KS, "The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey", Value Health, 7, pp.455~463 (2004)
11. Cardozo L, "Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial", BJU Int, 102, pp.1120~1127 (2008)
12. Cardozo L,A, "Increased warning time with darifenacin: A new concept in the management of urinary urgency", J Urol, 173, pp.1214~1218
13. Mattiasson A, "Standardization of outcome studies in patients with lower urinary tract dysfunction: a report on general principles from the Standardisation Committee of the International Continence Society", Neurourol Urodyn, 17, pp.249~253 (1998)
14. Choo MS, "Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study)", Int J Clin Pract, 62, pp.191~196 (2008)
15. Malone-Lee JG, "Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study", BJU Int, 103, pp.931~937 (2009)
16. Waldeck K, "Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland", J Urol, 157, pp.1093~1097 (1997)
17. Hughes KM, "Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers", Xenobiotica, 22, pp.859~869 (1992)
18. Kachur JF, "R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestin", J Pharmacol Exp Ther, 247, pp.867~872 (1988)
19. Versi E, "Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group", Obstet Gynecol, 95, pp.718~721 (2000)
20. Appell RA, "Overactive Bladder: Judging Effective Control and Treatment Study Group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study", Mayo Clin Proc, 76, pp.358~363 (2001)
21. Diokno AC, "OPERA Study Group. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial", Mayo Clin Proc, 78, pp.687~695 (2003)
22. Appell RA, "Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects", Mayo Clin Proc, 78, pp.696~702 (2003)
23. Dmochowski RR, "Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence", Urology, 62, pp.237~242 (2003)
24. Staskin DR, "Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study", J Urol, 181, pp.1764~1772 (2009)
25. Doroshyenko O, "Clinical pharmacokinetics of trospium chloride", Clin Pharmacokinet, 44, pp.701~720 (2005)
26. Rudy D, "Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment", BJU Int, 97, pp.540~546 (2006)
27. "Ballering-Brühl B, Höfner K, Jonas U. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability", World J Urol, 20, pp.392~399 (2003)
28. Rovner ES, "Trospium chloride in the management of overactive bladder", Drugs, 64, pp.2433~2446 (2004)
29. Menarini M, "TcP128-Study Group. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients?", Int J Clin Pharmacol Ther, 44, pp.623~632 (2006)
30. Diefenbach K, "Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years", BJU Int, 95, pp.346~349 (2005)
31. Lopez Pereira P, "Trospium chloride for the treatment of detrusor instability in children", J Urol, 170, pp.1978~1981 (2003)
32. Tsuchida S, "A comparative study of the effects of propiverine, terodiline, oxybutynin on the lower urinary tract function in the decerebrate dog", Hinyokika Kiyo, 36, pp.915~919 (1990)
33. Mazur D, "Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose-optimizing study", Scand J Urol Nephrol, 29, pp.289~294 (1995)
34. Stöhrer M, "Propiverine Investigator Group. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double- blind, multicenter clinical study", Eur Urol, 51, pp.235~242 (2007)
35. Madersbacher H, "Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohortstudy", BJU Int, 103, pp.776~781 (2009)
36. Madersbacher H, "A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence", BJU Int, 84, pp.646~651 (1999)
37. Dorschner W, "Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study", Eur Urol, 37, pp.702~708 (2000)
38. Stahl MM, "Ander- sson KE. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity", Neurourol Urodyn, 14, pp.647~655 (1995)
39. Clemett D, "Tolterodine: a review of its use in the treatment of overactive bladder", Drugs Aging, 18, pp.77~304 (2001)
40. Millard R, "Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity", J Urol, 161, pp.1551~1555 (1999)
41. Jacquetin B, "Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder", Eur J Obstet Gynecol Reprod Biol, 98, pp.97~102 (2001)
42. Sussman D, "Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET)", Curr Med Res Opin, 18, pp.177~184 (2002)
43. Sussman DO, "Onset of efficacy of tolterodine extended release in patients with overactive bladder", Curr Med Res Opin, 23, pp.777~781 (2007)
44. Siami P, "A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT)", Clin Ther, 24, pp.616~628 (2002)
45. Kreder K, "Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder", Eur Urol, 41, pp.588~595 (2002)
46. Choo MS, "Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study", Int J Clin Pract, 62, pp.1675~1683 (2008)
47. Homma Y, "Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial", BJU Int, 92, pp.741~747 (2003)
48. Lee JG, "Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder", Int J Urol, 9, pp.247~252 (2002)
49. Christoph F, "Long-term efficacy of tolterodine and patient compliance in pediatric patients with neurogenic detrusor overactivity", Urol Int, 79, pp.55~59 (2007)
50. Reddy PP, "Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity", J Pediatr Urol, 4, pp.428~433 (2008)
51. Fetscher C, "M (3) muscarinic receptors mediate contraction of human urinary bladder", Br J Pharmacol, 136, pp.641~643 (2002)
52. Haab F, "Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder", Eur Urol, 45, pp.420~429 (2004)
53. Chapple C, "A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder", BJU Int, 95, pp.993~1001 (2005)
54. Smulders RA, "Pharmacokinetics and safety of solifenacin succinate in healthy young men", J Clin Pharmacol, 44, pp.1023~1033 (2004)
55. Ikeda K, "M (3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland", Naunyn Schmiedebergs Arch Pharmacol, 366, pp.97~103 (2002)
56. Kobayashi S, "Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells", Life Sci, 74, pp.843~853 (2004)
57. Ohtake A, "In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats", Eur J Pharmacol, 492, pp.243~250 (2004)
58. Chapple CR, "Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study", BJU Int, 93, pp.71~77 (2004)
59. Chapple CR, "A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial", Eur Urol, 48, pp.464~70 (2005)
60. Haab F, "Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome", Eur Urol, 47, pp.376~384 (2005)
61. Garely AD, "Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT)", Clin Ther, 28, pp.1935~1946 (2006)
62. Malhotra B, "Pharma- cokinetic profile of fesoterodine", Int J Clin Pharmacol Ther, 46, pp.556~563 (2008)
63. Brynne N, "Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine", Clin Pharmacol Ther, 63, pp.529~539 (1998)
64. Nitti VW, "Efficacy, safety andtolerability of fesoterodine for overactive bladder syndrome", J Urol, 178, pp.2488~2494 (2007)
65. Chapple C, "Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder", Eur Urol, 52, pp.1204~1212 (2007)
66. Chapple CR, "Comparison of fesoterodine and tolterodine in patients with overactive bladder", BJU Int, 102, pp.1128~1132 (2008)
67. Wyndaele JJ, "Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study", Int J Clin Pract, 63, pp.560~567 (2009)
68. Kobayashi F, "Effects of imidafenacin (KRP-197", ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland, 2007, pp.57, 92~100
69. imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects, "Drug Metab Dispos", 2007, 1624~1633
70. Ohno T, "Population pharmacokinetic analysis of a novel muscarinic receptor antagonist, imidafenacin, in healthy volunteers and overactive bladder patients", Drug Metab Pharmacokinet, 23, pp.456~463 (2008)
71. Kanayama N, "Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes", Xenobiotica, 37, pp.139~154 (2007)
72. Homma Y, "Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder", Int J Urol, 15, pp.986~991 (2008)
73. Michel MC, "Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?", Naunyn Schmiedebergs Arch Pharmacol, 374, pp.79~85 (2006)
74. Staskin DR, "Overactive bladder in the elderly: a guide to pharmacological management", Drugs Aging, 22, pp.1013~1028 (2005)
75. Kay GG, "Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients", J Am Geriatr Soc, 54, pp.1004~1005 (2006)
76. Kay GG, "Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients", J Am GeriatrSoc, 53, pp.2195~2201 (2005)
77. Scheife R, "Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly", Clin Ther, 27, pp.144~153 (2005)
78. Asajima H, "QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman", Br J Clin Pharmacol, 66, pp.896~897 (2008)
79. MacDiarmid SA, "Overactive bladder: improving the efficacy of anticholinergics by dose escalation", Curr Urol Rep, 4, pp.446~451 (2003)
80. Gopal M, "Disconti- nuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms", Obstet Gynecol, 112, pp.1311~1318 (2008)

관련 논문AI추천